A Single-Dose Bioequivalence and Food Effect Study With Aprepitant and Fosaprepitant Dimeglumine in Healthy Young Adult Subjects.

Trial Profile

A Single-Dose Bioequivalence and Food Effect Study With Aprepitant and Fosaprepitant Dimeglumine in Healthy Young Adult Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Aprepitant (Primary) ; Fosaprepitant (Primary)
  • Indications Chemotherapy-induced nausea and vomiting; Postoperative nausea and vomiting
  • Focus Pharmacokinetics
  • Sponsors Merck & Co
  • Most Recent Events

    • 30 Jul 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top